Saturday 14 November 2026 Daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
Market analysisEnterprise
The business of pharma
Subscribe free
Earnings

Fulgent books $90.4m third-quarter sales and leaves 2026 revenue range untouched

The Nasdaq-listed diagnostics group tightened its expected annual adjusted loss and pointed to a cash-and-investments balance near $630m by December.

05 Nov 2026 · Fulgent Genetics, Inc. FLGT · Company news

Fulgent Genetics (NASDAQ: FLGT) reported sales of $90.4m for the three months to 30 September 2026, in results published on 5 November. The company framed the figure as roughly 8% higher, though the material reviewed for this report does not specify the comparison period.

Profitability remained negative. Fulgent booked a GAAP net loss of $13.2m for the quarter, against an adjusted (non-GAAP) loss of $2.4m. The roughly $10.8m gap between the two measures reflects adjustments whose composition was not available to CompePharma.

For the full year, management left its revenue target at $330m to $340m, so it did not move the top-line outlook after the third quarter. It did tighten the range for its adjusted loss to between $46m and $50m, a spread of $4m.

Fulgent also said it expects to end 2026 with about $630m in cash and investments. The full earnings release was not available, so the report cannot address test volumes, segment performance or the factors behind the quarter's numbers.

Why it matters

  • An unchanged $330m–$340m revenue range indicates no revision to Fulgent's full-year sales expectations as of early November 2026.
  • A narrower adjusted-loss band of $46m–$50m gives a clearer view of the expected cost of operating the business this year.
  • The projected year-end balance of about $630m in cash and investments is a relevant data point for those weighing Fulgent as a lab or testing partner.
  • Assessing specific test lines or services requires the full earnings release, which was not reviewed here.

Company's press release (SEC filing): Fulgent Genetics, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →